{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:03Z","timestamp":1786119363192,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/qai.0b013e3181b98537","type":"journal-article","created":{"date-parts":[[2009,11,20]],"date-time":"2009-11-20T09:44:48Z","timestamp":1258710288000},"page":"574-580","source":"Crossref","is-referenced-by-count":58,"title":["Virologic Response Differences Between African Americans and European Americans Initiating Highly Active Antiretroviral Therapy With Equal Access to Care"],"prefix":"10.1097","volume":"52","author":[{"given":"Amy C","family":"Weintrob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg A","family":"Grandits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K","family":"Agan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L","family":"Landrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy F","family":"Crum-Cianflone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica N","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia E","family":"Ord\u00f3\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn W","family":"Wortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210131","first-page":"537","article-title":"The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women.","volume":"39","author":"Anastos","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R2-7-20210131","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/QAI.0b013e31802f83a6","article-title":"Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care.","volume":"44","author":"Hartzell","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R3-7-20210131","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/QAI.0b013e31815ace7e","article-title":"The influence of psychosocial characteristics and race\/ethnicity on the use, duration, and success of antiretroviral therapy.","volume":"47","author":"Pence","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-7-20210131","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.2105\/AJPH.93.10.1728","article-title":"Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data.","volume":"93","author":"McGinnis","year":"2003","journal-title":"Am J Public Health"},{"key":"R5-7-20210131","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection.","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"R6-7-20210131","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/QAI.0b013e31815ac499","article-title":"Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV-therapy.","volume":"46","author":"Schackman","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-7-20210131","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/QAI.0b013e31816856c5","article-title":"Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.","volume":"47","author":"Tan","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-7-20210131","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1086\/344769","article-title":"The effect of race\/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients.","volume":"35","author":"Jensen-Fangel","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R9-7-20210131","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/00126334-200408010-00008","article-title":"Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-infected patients in the Netherlands.","volume":"36","author":"Nellen","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-7-20210131","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1468-1293.2005.00304.x","article-title":"Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy.","volume":"6","author":"Van den Berg","year":"2005","journal-title":"HIV Med"},{"key":"R11-7-20210131","doi-asserted-by":"crossref","first-page":"e1745","DOI":"10.1542\/peds.2006-0493","article-title":"Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection.","volume":"118","author":"Williams","year":"2006","journal-title":"Pediatrics"},{"key":"R12-7-20210131","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jama.296.7.769","article-title":"Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection.","volume":"296","author":"Gulick","year":"2006","journal-title":"JAMA"},{"key":"R13-7-20210131","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group Study.","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"R14-7-20210131","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and\/or nelfinavir: an Adult AIDS Clinical Trials Group Study.","volume":"192","author":"Haas","year":"2005","journal-title":"J Infect Dis"},{"key":"R16-7-20210131","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"key":"R17-7-20210131","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-139-10-200311180-00008","article-title":"Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 10(9) cells\/L.","volume":"139","author":"Wood","year":"2003","journal-title":"Ann Intern Med"},{"key":"R18-7-20210131","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/01.qai.0000147522.34369.12","article-title":"Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis.","volume":"38","author":"Nieuwkerk","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R19-7-20210131","first-page":"656","article-title":"Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.","volume":"169","author":"Wood","year":"2003","journal-title":"CMAJ"},{"key":"R20-7-20210131","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00042560-200004150-00005","article-title":"Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens.","volume":"23","author":"Gifford","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-7-20210131","doi-asserted-by":"crossref","first-page":"486","DOI":"10.7326\/0003-4819-146-7-200704030-00004","article-title":"Prevalence of neutropenia in the US population:age, sex, smoking status and ethnic differences.","volume":"146","author":"Hsieh","year":"2007","journal-title":"Ann Intern Med"},{"key":"R22-7-20210131","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archinte.1991.00400030063011","article-title":"Leukopenia, neutropenia, and decreased hemoglobin levels in healthy American blacks.","volume":"151","author":"Reed","year":"1991","journal-title":"Arch Intern Med"},{"key":"R23-7-20210131","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.humimm.2007.01.007","article-title":"Correlates of CD4+ and CD8+ lymphocyte counts in high risk immunodeficiency virus (HIV)-seronegative women enrolled in the Womens Interagency HIV Study (WIHS).","volume":"68","author":"Nowicki","year":"2007","journal-title":"Hum Immunol"},{"key":"R24-7-20210131","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.1993.00410070055008","article-title":"CD4 lymphocyte counts within 24 months of human immunodeficiency virus seroconversion. Findings in the US Navy and Marine Corps.","volume":"153","author":"Gorham","year":"1993","journal-title":"Arch Intern Med"},{"key":"R25-7-20210131","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1086\/383277","article-title":"Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.","volume":"189","author":"Mildvan","year":"2004","journal-title":"J Infect Dis"},{"key":"R26-7-20210131","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nm1741","article-title":"CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1 infected individuals.","volume":"14","author":"Ahuja","year":"2008","journal-title":"Nat Med"},{"key":"R27-7-20210131","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1086\/593104","article-title":"Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.","volume":"47","author":"Hoffmann","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R28-7-20210131","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1468-1293.2008.00564.x","article-title":"Impact of hepatitis B virus co-infection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study.","volume":"9","author":"Omland","year":"2008","journal-title":"HIV Med"},{"key":"R29-7-20210131","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1360-0443.2007.01841.x","article-title":"Substance use trends among active duty military personnel: findings from the United States Department of Defense Health Related Behavior Surveys, 1980-2005.","volume":"102","author":"Bray","year":"2007","journal-title":"Addiction"},{"key":"R30-7-20210131","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/00002030-200311210-00016","article-title":"Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort.","volume":"17","author":"Brodine","year":"2003","journal-title":"AIDS"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAI.0b013e3181b98537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:33Z","timestamp":1786039713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200912150-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181b98537","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}